Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 14;29(14):2561-2562.
doi: 10.1158/1078-0432.CCR-23-0807.

A CAPTIVATEing Analysis for Higher-Risk CLL

Kerry A Rogers
Editorial

A CAPTIVATEing Analysis for Higher-Risk CLL

Kerry A Rogers. Clin Cancer Res. .

Abstract

In an exploratory analysis of the phase II CAPTIVATE study, previously untreated patients with chronic lymphocytic leukemia with a higher-risk feature of immune globulin heavy chain variable (IGHV) unmutated status, del(17p), and/or TP53 mutation had similar efficacy and safety outcomes compared with patients without a higher-risk feature when treated with fixed-duration ibrutinib and venetoclax. See related article by Allan et al., p. 2593.

PubMed Disclaimer

Conflict of interest statement

K.A.R. received research funding from Genentech, AbbVie, and Novartis, consulted for Genentech, AbbVie, AstraZeneca, Beigene, Janssen, Innate Pharma, and Loxo@Lilly, and received travel funding from AstraZeneca.

Figures

Figure
Figure
In the CAPTIVATE study patients with IGHV mutated CLL had lower rates of uMRD in the bone marrow with treatment, but a higher percentage of patients were progression-free at 36 months. uMRD = undetectable minimal residual disease.
See this image and copyright information in PMC

Comment in

References

    1. Allan JN, Flinn IW, Siddiqi T, Ghia a, Tam CS, Kipps TJ, et al. Outcomes in Patients With High-Risk Features After Fixed-Duration Ibrutinib Plus Venetoclax: Phase 2 CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. Clinical Cancer Research 2023. - PMC - PubMed
    1. Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. NEJM Evidence 2022;1(7):EVIDoa2200006 doi doi:10.1056/EVIDoa2200006. - DOI - PubMed
    1. Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, et al. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk 2019;19(11):715–22 e6 doi 10.1016/j.clml.2019.07.004. - DOI - PubMed
    1. Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, et al. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J Clin Oncol 2021;39(36):4049–60 doi 10.1200/JCO.21.01181. - DOI - PMC - PubMed
    1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910–6 doi 10.1056/NEJM200012283432602. - DOI - PubMed

Publication types

MeSH terms